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Purpose: To investigate the effect of atropine on the development of spectacle lens induced myopia in the mouse and to
determine if the level of mRNAs for the muscarinic receptor subtypes (M1 - M5) is affected by atropine treatment.
Methods: Experimental myopia was developed in Balb/CJ (BJ) mice by placing −10 diopter spectacle lens on post-natal
day 10 over the right eyes of 150 mice (n=10 in each group, 5 repetitions) for six weeks. After 2 weeks of lens wearing,
the atropine group received a daily sub-conjunctival injection (10 µl) of 1% atropine sulfate and the saline group received
daily 10 µl of 0.9% normal saline for 4 weeks. In addition, myopia was developed in C57BL/6 (B6) mice by placing −10
D spectacle lens on post-natal day 10 over the right eyes of 60 mice (n=10 in each group, 2 repetitions) for six weeks with
and without atropine treatment. Refraction and axial length was measured at 2, 4, and 6 weeks after treatments. RT–PCR
and northern blots were performed using specific primers for M1-M5, and products sequenced. Real-time PCR was used
to quantify message levels.
Results: Axial length of myopic eyes was 111% of their controls without atropine treatment and 103% of controls after
atropine (p<0.01). Refraction shifted from myopic to emmetropic after atropine was administered in both pigmented and
non-pigmented  eyes.  Corneal  thickness,  anterior  chamber  depth,  corneal  curvature  and  retinal  thickness  were  not
significantly different with and without atropine treatment (p=0.14). The lens thickness and vitreous chamber depth were
significantly reduced after receiving atropine (p<0.05). Real-time PCR showed that message levels for M1, M3, and M4
were upregulated in myopic sclera after atropine treatment, but M2 and M5 showed little change.
Conclusions: The present study shows that 1% atropine reduces myopia progression in both pigmented and non-pigmented
mice eyes. Axial length and vitreous chamber depth appear to be the main morphological parameters related to myopia.
The results suggest that atropine may act on one or more muscarinic receptors to differentially regulate expression levels
of specific receptors.
The  cardinal  optical  characteristic  of  myopia  is  axial
elongation of the posterior segment of the eye, which is due
to scleral growth and remodeling [1-4]. Axial elongation is
believed to be mediated by alterations in the connective tissues
of the sclera [3,4], part of the collagenous outer tunic of the
eye.  To  date,  atropine  (a  pan-muscarinic  antagonist)  has
proven  to  be  a  promising  pharmacological  agent  that
significantly reduced the progression of myopia in several
clinical trials [5,6] including the ATOM (Atropine Treatment
Of Myopia) study that was conducted in our center [7]. In a
recent publication we demonstrated that the mouse and human
scleral  fibroblasts  express  all  five  types  of  muscarinic
receptors [8]. However, it remains to be shown that atropine
also halts the progression of myopia in the mouse model [9].
Atropine has been extensively tested in animal models.
Suppression of deprivation myopia was studied with atropine
treatment  in  tree  shrews  [10],  chicks  [11,12]  and  rhesus
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monkeys [13]. Since the mouse has recently been used as a
new model [14,15] to study biologic aspects of myopia, the
effects of atropine on experimental myopia are important to
examine.
It is reasonable to expect that the mechanism of action of
muscarinic  receptor  antagonists  in  inhibiting  myopia
progression to be consistent across species. Although atropine
[16,17] and pirenzepine (specific muscarinic receptor 1 (M1)
antagonist) [18] have both been shown to reduce myopia
progression  via  slowing  of  axial  elongation,  the  exact
mechanism is still unknown. It was found that the M1 receptor
does not exist in the chick sclera [19] such evidence implies
that muscarinic antagonists which prevents the progression of
myopia in the chick either work through another muscarinic
receptor  subtype  or  through  non-specific  or  non-receptor
mediated mechanisms. It is important to investigate the gene
expression pattern during myopic development or progression
may offer a productive avenue for future research.
The purpose of this study was to investigate the effect of
atropine in a mouse model of experimental myopia and to
determine if atropine prevents axial elongation after induction
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680of spectacle lens induced myopia. The experimental myopia
was developed in two different strains to determine the effect
of spectacle lens induction in pigmented and non-pigmented
eyes.  Scleral  fibroblast  message  levels  for  the  muscarinic
subtypes (M1 - M5) were also analyzed in conjunction with
atropine treatment during myopia progression.
METHODS
Animals: Pregnant BJ mice (Mus musculus) and B6 mice were
obtained  from  the  animal  holding  unit  of  the  National
University of Singapore. Animals gave birth in our animal
holding unit. Naive control animals were housed in groups of
6 while experimental animals were housed individually in
standard mouse cages after 28 days of age at 25 °C on a
schedule of 12:12 h of light on and off with mouse pellets and
water available ad libidum. Approval was obtained from the
SingHealth Institutional Animal Care and Use of Committee
(IACUC) and all procedures performed in this study complied
with  the  Association  of  Research  in  Vision  and
Ophthalmology (ARVO) Statement for the Use of Animals in
Ophthalmology and Vision Research.
Treatment protocols: The effects of atropine treatment were
examined using spectacle lens-induced myopia and allocated
to one of three groups: One group (n=10, 5 batch) received a
daily  10  μl  of  1%  sub-conjunctival  injections  of  atropine
sulfate (ATG), and the other group (n=10, 5 batch) received
daily 10 μl of 0.9% of sterile normal saline (NSG) as a vehicle,
and the third group (n=10, 5 batch) was treated with spectacle
lens  alone  to  induce  myopia.  The  right  was  used  as  a
experimental and left eye was served as contra-lateral control
in all groups. The same study was conducted in B6 mice
(n=10,  2  batch  in  each  group)  with  −10  diopter  (D)  to
investigate the effect of strain difference with lens treatment.
In all the remaining experiments, BJ treated mice samples
were used.
Sub-conjunctival injections were administered to both
eyes at the same time each day (approximately 9:00 AM)
commencing  on  the  24th  day  (2  weeks  after  initiation  of
spectacle lens treatment). A compatible level of atropine was
determined before the in vivo use in a tissue culture study with
mouse scleral fibroblasts [8]. These concentrations (0.01%
[147.929 µM], 0.1% [1479.29 µM], 0.5% [7396.45 µM], and
1% [14792.9 µM]) were then tested in vivo in a small pilot
study. From our pilot study, we found that 0.5% and 1%
atropine significantly reduced the elongation of axial length
(data not shown). In this study, we are reporting results from
the 1% atropine treatment. The injection (31.5 gauge needle)
was  performed  under  sterile  conditions  and  microscopic
control. For this procedure, mice were anaesthetized with
0.05–0.1  ml  (IP)  of  a  mixture  of  0.2  ml  10%  ketamine
hydrochloride  and  0.1  ml  2%  xylazine  hydrochloride,
dissolved in 1.0 ml sterile saline. The eyes were examined
daily and no infections were found. This treatment schedule
continued  for  four  weeks  starting  on  post-natal  day  24
continued until post-natal day 52. All measurements were
taken  at  post-natal  day  52,  the  equivalent  of  6  weeks  of
spectacle lens wear.
Refraction  and  axial  length:  Refractions  and  biometry
measurements were recorded every week until the end of the
study. Axial length, lens thickness, vitreous chamber depth
and corneal diameter were measured with in vivo Optic Low
Coherence Interferometry (OLCI-AcMaster). Refraction was
measured by automated eccentric photorefractor. Details of
the methods were previously described [14,15]. The corneal
radius  of  curvature  was  measured  in  vivo  by  automated
infrared photo-keratometry in B6 mice at all time points.
Histological studies: Six eyes from each of the atropine and
saline  treated  groups  were  fixed  in  freshly  prepared  4%
paraformaldehyde, pH 7.4 at room temperature (RT) for 24 h.
Tissues were embedded in JB-4 plastic (Electron Microscopy
Sciences, Hatfield, PA) overnight. Processed sections were
stained  with  hematoxylin  and  eosin  before  coverslipping.
Tissues  were  observed  under  light  a  microscope
(LWDPL40xFPL-6,  Olympus  with  a  Nikon  CoolpiX-995
Digital  Camera  (Olympus,  Center  Valley,  PA)  to  record
images)  and  sclera  thickness  measured  using  an  ocular
micrometer  at  40×  magnification.  Measurements  were
obtained from three locations: just posterior to the limbus, at
the equator and immediately lateral to the optic nerve head.
For each location, three adjacent fields were measured and
then averaged. Six sections from each eye were placed on a
slide and the measurements were made from five individual
mouse eye sections. The values used for each calculations
represents the mean of ninety values for each locations.
RNA Isolation and RT–PCR: Total RNA was isolated using
TRIzol reagent (Invitrogen life technologies, Carlsbad, CA)
in accordance with the manufacturer’s instructions [20]. Pairs
of eyes were enucleated. The retina and choroid were stripped
away  from  the  sclera  and  immediately  frozen  in  liquid
nitrogen.  Six  different  tissue  samples  were  analyzed:  1.
Atropine treated myopic sclera (AMS), 2. Control sclera from
atropine  treated  mice  (AMCS),  3.  Normal  saline  treated
myopic sclera (NSMS), 4. Normal saline treated control sclera
(NSMCS), 5. Naive sclera (S) and 6. mouse cerebellum (C).
Ten eyes were separately pooled and packed into aluminum
foil and frozen as one sample. This experiment was repeated
five times with different batches for all five tissues (n=10 in
each group from 3 batch). A single pool of RNA from the
cerebellum  of  three  naive  mice  was  used  throughout  the
experiments as a control. In addition to the above mentioned
tissues, myopic sclera (MS) and contra-lateral control sclera
(CS) samples were also used for real-time PCR experiments
(described  below).  PCR  was  performed  as  previously
described [8].
Northern  blotting:  Northern  blot  hybridizations  were
performed as previously described [21]. Briefly, 25 µg of total
RNA was loaded in each lane, run on a 1% agarose gel,
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681transferred  to  a  positively  charged  nylon  membrane,  and
hybridized to a fluorescein-labeled mouse M1 EcoRI enzyme
digested insert cDNA clone.
Real-Time Comparative PCR: Real-Time comparative PCR
was performed in a 96-well microtiter plate format on an ABI
PRISM  7700  Sequence  Detection  System  (PE  Applied
Biosystems,  Foster  City,  CA)  equipped  with  a  Sequence
Detection System (SDS) software version 1.6.3. PCR was
performed  using  250  ng  of  cDNA  of  each  sample.  The
primers/probes for muscarinic receptor subtypes; M1-M5 were
obtained  from  Taqman,  Assays  On  Demand,  PE  Applied
Biosystems. Primer sequences and conditions are presented
in Table 1 Quantum RNA classic II 18S Internal Standard
(Ambion, Austin, TX) was used as an endogenous control.
The detailed method was previously described [14] and data
was  analyzed  by  comparative  CT  (ΔΔCT)  method  as
previously described [22].
Data Analysis: Independent t-tests were used to analyze the
means of the axial length, scleral thickness, and the refraction
of the eyes. A difference at p value <0.05 was considered
statistically significant. Data are reported as the mean±SD.
The statistical significance of changes in M1 - M5 mRNA
levels  was  analyzed  using  Student’s  t-test.  The  Mann–
Whitney U-test was used to determine differences between
groups.
RESULTS
Atropine treatment reduced axial elongation, lens thickness
and vitreous chamber depth: Spectacle lens induction for a
period of 42 days resulted in statistically significant in axial
elongation, increased vitreous chamber depth of the treated
eyes in BJ (p<0.01, n=50) and B6 mice (p<0.05, n=20) when
compared to the contra-lateral control eyes. However the axial
elongation, lens thickness, and vitreous chamber depth was
appeared to be most significant in the BJ treated eyes as
compared to the B6 treated eyes. There was no significant
difference in corneal thickness and anterior camber depth
between lens treated and contra-lateral eyes in both strains.
(Figure 1A-E). Daily injections of the normal saline vehicle,
into spectacle lens induced eyes did not alter the change in
axial elongation, lens thickness and vitreous chamber depth
in BJ (p<0.01, n=50) and B6 mice (p<0.05, n=20). Daily
injections of atropine, at a concentration of 1%, blocked most
of  the  elongation  of  axial  length,  lens  thickness  and  the
vitreous  chamber  depth  associated  with  spectacle-lens
induced myopia, but did not significantly affect the rate of
axial elongation in contra-lateral control eyes. The other eye
biometry measurements were not significantly different in
treated or control eyes in non-pigmented and pigmented mice
(Figure 2A-E and Figure 3A-E, respectively).
Refractive  error  changes  with  atropine  treatment:  Eyes
wearing −10 D lens in both non-pigmented and pigmented
mice, the refraction was shifted from hyperopic to myopic
(Figure  1F,  p<0.01,  n=50  and  n=20,  respectively)  after  6
weeks of induction. Eyes wearing −10 D lens, treated with
atropine  sulfate  for  4  weeks  was  shifted  from  myopic  to
hyperopic in both strains (Figure 2F, p<0.01, n=50 and 3F,
p<0.01, n=20, respectively) were significant when compared
to normal saline treatment. Whereas the minus lens wearing
eye, treated with saline for 4 weeks was still showed a myopic
shift in both strains (Figure 2F and Figure 3F, respectively).
This result indicates that the atropine treatment reduces the
progression of myopia and not the saline vehicle treatment.
There was no significant difference seen in the contra-lateral
control  eyes  in  both  strains  (Figure  2F  and  Figure  3F,
respectively).  In  B6  mice,  the  minus  lens  wearing  eye’s
corneal curvature was slightly flatter than the control and
atropine treated eyes (Figure 3G). This was significant at 4
and 6 weeks after induction of myopia (p<0.05, n=20).
Comparative analysis by real time PCR: Data from three
different comparisons was analyzed. Seven different tissues
were  used  for  quantification  of  muscarinic  receptor  gene
expression: 1. MS (minus lens wearing), 2. CS (no lens), 3.
AMS (minus lens with atropine), 4. AMCS (no lens with
atropine) 5. NSMS (minus lens with saline), 6. NSMCS (no
lens  with  saline),  7.  S  (Naive  sclera),  8.  Mouse  Brain
TABLE 1. ACCESSION NUMBER OF GENES IN THE NUCLEOTIDE SEQUENCE DATABASE (NCBI), SEQUENCES OF USED PRIMER PAIRS AND LENGTH
OF THE AMPLIFIED SEQUENCES
Gene Primer sequences Size Accession number Percent homology
M1 F: F: 5′ TCCCTCACATCCTCCGAAGGTG-3′ 139 bp NM_007698 99%
R: R: 5′CTTTCTTGGTGGGCCTCTTGACTG-3′
M2 F: F: 5′-CTGGAGCACAACAAGATCCAGAAT-3′ 69 bp NM_203491 100%
R: R: 5′-CCCCCTGAACGCAGTTTTCAGT - 3′
M3 F: F: 5′-GCAAGACCTCTGACACCAACT-3′ 91 bp NM_033269 100%
R: R: 5′-AGCAAACCTCTTAGCCAGCG-3′
M4 F: F: 5′-CGGCTACTGGCTCTGCTACGTCAA-3′ 122 bp NM_007699 100%
R: R: 5′-CTGTGCCGATGTTCCGATACTGG-3′
M5 F: F: 5′-TAGCATGGCTGGTCTCCTTCA-3′ 76 bp NM_205783 100%
R: R: 5′-CGCTTCCCGACCAAGTACTG-3′
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682cerebellum was used as positive control and 18s rRNA was
used as endogenous internal control for analysis.
Gene  expression  of  myopic  and  atropine  treated  myopic
sclera: Initially, CT values for M1-M5 in MS and AMS were
compared against NSMS of muscarinic receptors gene CT
values after normalizing with 18s rRNA. Similar analysis
method was applied to the control group. M1, M3, and M4
mRNA levels were upregulated in the AMS and AMCS. In
contrast, M2 and M5 mRNA levels were down regulated in the
AMS and AMCS (Figure 4A). There were no changes in the
MS and CS M1-M5 mRNA levels.
Normalized fold change expression of M1-M5 in AMS as
compared with NSMS were 11, −8, 9, 8.5, −9.2 fold change
(p<0.01, n=5 experimental repeats), respectively. The effects
of atropine on message levels for M1, M3, and M4 were greater
in experimental myopic eyes than the contra-lateral control
(non-myopic) eyes. Similarly atropine effect on M2 and M5
was much greater in experimental myopic eyes than control
eyes. It was reported that atropine reduces the axial length
even in the naive eyes [23,24] however the effect was much
higher in the spectacle lens wearing eyes.
Gene expression of myopic, atropine treated, saline treated
compared with contra-lateral control sclera: Message levels
for the muscarinic receptors from MS was compared against
the CS from the same animal using the gene CT value after
normalizing  with  18s  rRNA.  Normalized  fold  change
expression of M1 (−2.12 fold), M3 (−2.27 fold), and M4 (−2.02)
mRNA levels were down-regulated in the MS and NSMS
(−1.93 fold, −2.09 fold and −1.83 fold, respectively; p<0.01)
whereas M1, M3, and M4 mRNA levels were upregulated after
receiving  atropine  (10.58  fold,  5.01  fold  and  6.78  fold,
respectively; p<0.01). In contrast, M2 (2.98 fold) and M5 (3.47
fold) mRNA levels were upregulated in the MS and NSMS
(1.96 fold, 2.3 fold respectively; p<0.01). This was opposite
in the AMS (M2: −2.28 and M5: −5.39 fold; Figure 4B).
Analysis showed that atropine effect on M1 was much
greater  in  MS  as  compared  to  their  control  after  being
normalized with 18s rRNA than on M4 and M3 (125%, 115%,
and 112%, respectively; p<0.01). Similarly atropine effect on
M5 was much greater in MS than it was on M2 (116%. and
101%, respectively; p<0.01). Our results showed that M1,
M3, and M4 levels of scleral mRNA reduction, which led to
Figure  1.  This  graph  represents  the
ocular  biometry  of  Balb/CJ  (BJ)  and
C57BL/6  (B6)  mice  with  −10  D
spectacle lens induced myopia. The lens
was applied at post-natal day 10 (before
eye  opening).  The  ocular  biometry
measurements  were  measured  using
OLCI-AcMaster (in vivo: accuracy ±10
microns) and refraction (diopters) was
measured  by  automated  infrared
photorefractor at 2 weeks, 4 weeks, and
6 weeks after induction of myopia. The
BJ  and  B6  mice  ocular  biometry
measurements  (mm)  were  plotted
against  lens  weraing  period  (weeks).
The corneal thickness (A) and anterior
chamber depth (B) was not significantly
different  when  comparing  the  lens
treated  eyes  against  contra-lateral
control eyes in both strains. The lens
thickness (C), vitreous chamber depth
(D), axial length (E), and refraction (F)
were  significant  after  4  weeks  and  6
weeks  of  induction  in  both  strains.
However  when  comparing  the  both
strains, Balb/CJ mice eyes were more
significant (n=50, p<0.01) at 6 weeks of
minus  lens  wearing.  Spectacle  lens-
induced  myopia  caused  elongation  of
the globe and reduced hyperopia. Data
was  represented  as  mean±S.D,  *
represents significance level p<0.05 and
** represents significance level p<0.01.
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683the suppression of excessive axial elongation while M2 and
M5 showed little change.
Gene expression of experimental and control sclera against
naive  sclera:  Experimental,  control  scleral,  and  mouse
cerebellum  muscarinic  receptor  subtypes  CT  values  were
compared against naive sclera of M1-M5 CT values after being
normalized with 18s rRNA. M1 mRNA levels were down
regulated  (−9.52  fold)  after  the  induction  of  myopia  and
treated with normal saline (−9.22 fold) and this expression
pattern was reversed with atropine treatment (4.34 fold). The
mRNA level of M3 and M4 showed a similar expression trend
to that of M1. In contrast, M2 and M5 mRNA levels were
upregulated in MS and NSMS whereas it was highly down
regulated in the AMS (Figure 4C). The atropine effect on
M1, M2, and M4 was much greater in experimental myopic eyes
when compared to naive sclera.
In all set of data, MS and NSMS gene expression patterns
for M1-M5 was similar but not the exact values as expected.
The morphological and structural changes of sclera in both
treatments were not different. Moreover, the mRNA levels
were slightly different in these 2 groups of sclera; this may be
due to some external stress received during saline injection or
other factors involved.
Northern blot analysis: To corroborate the positive results
obtained from PCR, northern blots, a standard method for
detection of mRNA levels, were performed. At the same time
northern blots also provide a direct comparison of message
abundance between samples on a single membrane. Northern
blot analysis confirmed the same pattern of gene expression
for all five M1-M5 in the minus lens treated sclera (Figure 5A),
lens with atropine or normal saline treated experimental sclera
and control sclera (Figure 5B) as like Real-Time PCR results.
Expression of muscarinic receptor subtypes: RT–PCR was
performed  on  sclera  from  mice  treated  with  minus  lens,
receiving  atropine  and  normal  saline  in  conjunction  with
development of myopia, contra-lateral controls, and naive
sclera at the end of each experiment. It was determined that
M1-M5 was differentially expressed in mice treated with minus
lens  with  and  without  drug  treatment  and,  contra-lateral
Figure  2.  Atropine  sulfate  (pan
muscarinic  antagonist)  and  normal
saline treated BJ mice ocular biometry
measurements  were  plotted  against
induction  period  (weeks).  One  group
was  treated  with  sub-conjunctival
injection  of  1%  atropine  sulfate  (pan
muscarinic  antagonist)  and  another
group  was  treated  with  0.9%  normal
saline  for  four  weeks.  The  drug
treatment was started after 2 weeks of
minus lens wearing. Four weeks after
drug  treatment,  refractive  error  and
ocular biometry determined as before.
The corneal thickness (A) and anterior
chamber depth (B) was not significantly
different with or without drug treatment.
The  lens  thickness  (C),  vitreous
chamber depth (D) and axial length (E)
were  significantly  reduced  after
receiving  atropine  and  there  was  no
effect with saline treatment. The myopic
eye received atropine sulfate was shifted
from  myopic  to  hyperopic  when
compared to saline treated myopic eye
was till at myopic shift (F). There was
no  significant  difference  seen  in  the
control  eyes.  Spectacle  lens-induced
myopic  eye  received  1%  atropine
reduced the myopia progression and not
with  saline  treatment.  This  result
confirms  that  1%  atropine  reduces
myopia progression in mice. Data was
represented as mean±S.D, * represents
significance  level  p<0.05  and  **
represents significance level p<0.01.
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684control  sclera  (Figure  6A,B,  respectively).  In  preliminary
studies it was found that the pigment epithelium was often
closely adherent to the sclera. Therefore, a procedure was
developed to quickly remove the pigment epithelium, which
was  checked  by  histological  evaluation  of  sections  from
different regions of the sclera. Therefore the PCR results were
considered to represent only the sclera fibroblasts [8].
Atropine treatment reversed scleral thinning: As known from
previous observations in the normal mammalian eye, it was
found  in  the  mouse  that  scleral  thickness  increased  from
anterior  to  posterior  in  naive  and  control  eyes.  Scleral
Figure  3.  Atropine  sulfate  (pan
muscarinic  antagonist)  and  normal
saline treated B6 mice ocular biometry
measurements  were  plotted  against
induction  period  (weeks).  One  group
was  treated  with  sub-conjunctival
injection  of  1%  atropine  sulfate  (pan
muscarinic  antagonist)  and  another
group  was  treated  with  0.9%  normal
saline  for  four  weeks.  The  drug
treatment was started after 2 weeks of
minus lens wearing. Four weeks after
drug  treatment,  refractive  error  and
ocular biometry determined as before.
The corneal thickness (A) and anterior
chamber depth (B) was not significantly
different with or without drug treatment.
The  lens  thickness  (C),  vitreous
chamber depth (D) and axial length (E)
were  significantly  reduced  after
receiving  atropine  and  there  was  no
effect with saline treatment. The myopic
eye received atropine sulfate was shifted
from  myopic  to  hyperopic  when
compared to saline treated myopic eye
was till at myopic shift (F). There was
no  significant  difference  seen  in  the
control eyes. The corneal curvature was
determined  by  automated
photokeratometry.  The  minus  lens
wearing  eye’s  corneal  curvature  was
slightly  flatter  than  the  control  and
atropine  treated  eyes  (G).  This  was
significant  at  4  and  6  weeks  after
induction  of  myopia.  Spectacle  lens-
induced  myopic  eye  received  1%
atropine for 4 weeks was significantly
reduced  the  axial  elongation,  lens
thickness  and  vitreous  chamber
elongation however there was no effect
with  saline  treatment.  This  result
suggests  that  1%  atropine  reduces
myopia progression in mice and also no
difference  in  strains.  These  results
confirm  that  atropine  is  effective  in
reducing  myopia  progression  in  both
pigmented  and  non-pigmented  eyes.
Data  was  represented  as  mean±S.D,
*represents  significance  level  p<0.05
and  **represents  significance  level
p<0.01.
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685Figure 4. Relative gene expression of
muscarinic  receptor  1-5  to  the
corresponding atropine treated mRNA
level with and without myopia. A: Bar
graph  depicting  the  relative  gene
expression of muscarinic receptor 1–5
of  myopic  (MS)  and  atropine  treated
myopic (AMS) sclera ∆CT values to the
corresponding  normal  saline  treated
(NSMS)  sclera  mRNA  level  after
normalization with 18S rRNA internal
standard. Similar analysis method was
applied to the control group (NSMCS).
The mRNA level of M1, M3, and M4 after
atropine treatment in the experimental
myopic sclera (AMS) was upregulated
and  some  change  observed  in  the
atropine  treated  control  (AMCS)
whereas down regulated during myopia
(MS)  and  after  receiving  saline
(NSMS). The mRNA levels of M2 and
M5  after  induction  of  myopia  were
upregulated  and  reversed  (down-
regulated)  in  atropine  treated  group.
Data was represented as mean±SD B:
Bar graph depicting the relative gene
expression of muscarinic receptor 1–5
of  myopic  (MS),  atropine  treated
myopic  (AMS)  and  normal  saline
treated  myopic  (NSMS)  sclera  ∆CT
values to the corresponding their own
contra-lateral control mRNA level (CS,
AMCS, and NSMCS, respectively) after
normalization with 18S rRNA internal
standard. The mRNA levels of M1, M3,
and M4 after induction of myopia and
treated with normal saline were down
regulated and reversed (upregulated) in
atropine  treated  group.  The  mRNA
levels of M2 and M5 after induction of
myopia and treated with normal saline
were upregulated and reversed down-
regulated in the atropine treated sclera.
Data was represented as mean±SD C:
Bar graph depicting the relative gene
expression of muscarinic receptor 1–5
of cerebellum, myopic (MS), atropine
treated  myopic  (AMS),  normal  saline
treated myopic (NSMS), contra-lateral
control  (CS),  atropine  treated  control
(AMCS)  and  normal  saline  treated
control (NSMCS) sclera ∆CT values to
the corresponding the naive sclera (S)
mRNA  level  after  normalization  with
18S  rRNA  internal  standard.  The
mRNA levels of M1, M3, and M4 after
induction of myopia and treated with
normal saline were down regulated and
reversed  (upregulated)  in  atropine
treated group. The mRNA levels of M2
and M5 after induction of myopia and
treated  with  normal  saline  were
upregulated and opposite in the atropine
treated group. Data was represented as
mean±SD.
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686thickness was measured from photomicrographs using the
calibrated stage micrometer (accuracy ±7.0 µm) for as well as
by magnified video imaging using trans-illuminated globes
(accuracy ±4.0 µm). As shown in Table 2 (all at a level of
p<0.05,  n=6  in  each  group  from  3  batch),  spectacle  lens
induced myopia (Figure 7A) combined with daily injections
of normal saline resulted in reductions in scleral thickness at
equatorial and posterior locations (Figure 7C) when compared
to aged-matched untreated eyes (Figure 7B) and with only
normal saline without lens treatment (Figure 7D). Spectacle
lens induced myopia with daily injection of atropine sulfate,
at a concentration of 1%, blocked the posterior scleral thinning
Figure 5. Northern blot analysis. Northern blot of M1-M5 mRNA expression in 6 weeks minus lens treated sclera (A) and with atropine or
saline treated sclera (B). Total RNA (25 µg) was loaded in each lane, run on a 1% agarose gel, transferred to a positively charged nylon
membrane, and hybridized to a fluorescein-labeled mouse M1 EcoRI enzyme digested insert cDNA clone. In the upper panel the sizes of 28S
(4.7 kb), 18S (1.9 kb) rRNA and M1-M5 (2.6 kb, 1.8 kb, 3.2 kb, 1.6 kb and 3.5 kb, respectively) are indicated to the left. A: Lane 1: Mouse
brain cerebellum (positive control), lane 2: minus lens treated myopic sclera, lane 3: minus lens control sclera, lane 4: naive sclera. B: Lane
1: atropine treated myopic sclera, lane 2: atropine treated control sclera, lane 3: saline treated myopic sclera, lane 4: saline treated control
sclera.
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687(Figure  7E),  this  was  closely  similar  to  their  fellow  eyes
without lens treatment (Figure 7F).
DISCUSSION
In this study, BJ mouse was used to induce experimental
myopia as per prior established method [14]. Experimental
myopia was achieved for our study even though we had used
albino strain which suggests that visual cortex is not important
to control the excessive expansion of the posterior segment of
the  eye  or  refractive  error  changes  in  mouse.  Our  results
attained  were  similar  to  past  reported  studies  of  different
species which are elaborated below [25-28]. Deprivation of
various  parts  of  the  visual  field  produces  myopia  and
elongation even in animals with optic nerve severed or those
affected by degraded retinal image (even if it is in one sector
of the eye) impling that accommodation is not involved. The
mechanism  by  which  the  nervous  system  influences  eye
growth appears to be different even in closely related primate
species which exhibit different responses to form deprivation
conditions, suggesting differing mechanisms of eye growth
control. Paralysis of the ciliary muscle or optic nerve section
does not prevent the development of myopia in the rhesus
macaque, indicating that in this species the axial growth is
controlled by the retina. These results suggest that some factor
in part of the retina can influence the growth of the sclera or
the level of the scleral ocular elongation results from local
growth, because we found increases in scleral fibroblasts cell
proliferation in the induced eye (data not shown). It implies
that the control of eye growth by vision seems to take place
in local regions of the eye.
B6 mice were also used in our study to determine the
effect of atropine in pigmented eyes with myopia. The results
confirm that both pigmented and non-pigmented eyes were
influenced by the minus lens treatment. Elongation of axial
length and vitreous chamber depth appeared to be the main
morphological parameters related to myopia in both strains.
Moreover the axial length elongation was most significant in
BJ mice when compared to B6 mice which indicates that the
Figure 6. Gene expression of muscarinic receptor 1-5 prior to and after induction of experimental myopia with atropine treatment. RT–PCR
results for M1-M5 gene expression in 6 weeks minus lens treated sclera (A) and with atropine or saline treated sclera (B). A: Lane 1: DNA
ladder, lane 2: Mouse brain cerebellum (positive control), lane 3: minus lens treated myopic sclera, lane 4: minus lens control sclera, lane 5:
naive sclera, lane 6: water (negative control). B: Lane 1: DNA ladder, lane 2: atropine treated myopic sclera, lane 3: atropine treated control
sclera, lane 4: saline treated myopic sclera, lane 5: saline treated control sclera, 6: water (negative control). C: 18s rRNA was also loaded in
parallel to detect the DNA contamination for all samples used.
TABLE 2. SPECTACLE LENS, ATROPINE, AND SALINE TREATED GROUP MICE SCLERAL THICKNESS VERSUS CONTRA-LATERAL CONTROL SCLERAL THICKNESS.
Dimensions (µm) Ex (Atr) Con (Atr) Ex (NS) Con (NS) Ex Con Naive Age (Days)
Anterior Sclera 16.7±0.06 16.7±0.10 16.4±0.02 16.9±0.07 16.5±0.06 16.6±0.08 16.9±0.10 52
Equator Sclera 32.3±0.08 31.7±0.08 22.6±0.10 30.8±0.13 22.2±0.09 31.0±0.10 31.8±0.12 52
Posterior Sclera 70.5±0.05 71.2±0.03 53.9±0.05 70.9±0.09 53.2±0.08 71.1±0.09 71.7±0.11 52
        Ex (Atr)=atropine treated myopic eye, Con (Atr)=atropine treated control eye, Ex (NS)=normal saline treated myopic eye, Con
        (NS)=normal saline treated control eye, Ex=myopia induced eye, Con=control eye. Values are represented as mean ±S.D,
        significance at p<0.05, n=10 for each group.
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688eye growth was higher in the BJ mice with age or with minus
lens treatment.
Atropine  was  injected  sub-conjunctively  through  the
upper  bulbar  conjunctiva,  a  route  that  optimizes  scleral
exposure to the drug to determine the muscarinic receptor
gene expression pattern during myopia development. It has
been  proposed  that  muscarinic  antagonists  might  produce
their effect by acting directly on scleral muscarinic receptors;
however, that hypothesis is still being investigated [29]. We
have  confirmed  that  atropine  effectively  reduced  axial
elongation in mouse eyes undergoing spectacle lens treatment
to  induce  myopia.  Atropine  did  not  impose  significant
changes in the axial length of control eyes, which received
clear visual input. This finding is in agreement with previous
studies that investigated the effects of atropine on FDM in
chicks [11,12], in tree shrews [30] and in monkeys [13,31,
32].  Atropine  has  been  shown  to  effectively  prevent  the
progression of human juvenile myopia [33,34]. In mouse, the
atropine reduces the eye growth at both low (data not shown)
and high doses (this study) but the role of muscarinic receptors
remains unclear. The application of anti-muscarinic drugs
were able to change collagen structure and production of
scleral extracellular proteins during myopia development in
animal models [35,36]. This tend to suggest that investigation
of scleral remodeling by atropine in the mouse model may be
a good strategy to discover other anti-myopiagenic drugs for
humans.
The  mouse  sclera,  a  connective  tissue  consisting  of
fibroblasts embedded in an extracellular matrix (ECM) of
largely collagen Type I and proteoglycans, defines the shape
and axial length of the eye. Because both biochemical analysis
and histological analysis showed, significant changes only
occur within the posterior region of sclera in chick model
[37,38]  but  without  evidence  in  the  mouse  model,  the
histological study was performed on the whole sclera. From
our findings, in anterior and equator sclera of experimental
eye, there was no obvious change when compared to that of
control eyes. As such, the posterior sclera was thinner than
that of control eye. These results are consistent with those
from the chick [39]. The fibrous sclera responds in the same
manner  across  species  (birds,  mammals,  and  human)  in
response to hyperopic defocus or form deprivation stimuli,
Figure 7. Light micrographs of plastic-embedded mouse posterior sclera. Photomicrograph of posterior scleral thickness of spectacle lens
treated (A) and control sclera (B). Normal saline treated myopic (C) and contra-lateral control eyes (D, n=6 eyes, 6 sections from each eye),
40× original magnification. There was no effect of normal saline on the posterior scleral thickness of myopic sclera. Lens treatment with and
without normal saline reduced the sclera thickness which shows that scleral thinning occurred during myopia development and there was no
effect of normal saline treatment in the myopia progression. Atropine treated myopic (E) and atropine treated contra-lateral control eyes (F,
n=6 eyes, 6 sections from each eye), 40× original magnification. Atropine sulfate was increased the posterior scleral thickness which shows
that 1% atropine was effective in the myopia progression in mouse. Arrow indicates the sclera and box indicates the thickness. Scale bar=50
μm. Black arrows indicate the sclera and white circles show the scleral fibroblasts.
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689thinning in experimental eyes. The change in axial length
could  potentially  be  attributed  to  changes  in  posteriorly
located ocular tissues, such as vitreous, retina or sclera. These
ambiguous findings suggest that in the chick, atropine may
work via other mechanism to inhibit myopia development
because it was reported that the chick does not possess a
functional  M1  receptor  [19].  It  would  be  important  to
determine  if  muscarinic  antagonists  interact  with  other
pathways implicated in the regulation of ocular growth.
M1, M3, and M4 gene expression levels were upregulated
in  sclera  of  the  experimental  eyes  following  atropine
treatment. After the treatment, myopic sclera produced less
message for M2 and M5 and more in saline treated myopic
sclera. This is the first study that reports differential regulation
and  expression  of  mRNA  levels  following  chronic
administration of atropine in experimentally induced myopic
mice. Comparison of these results with those of previous
studies on rat brain [40], chick cerebral neurons [41], and rat
cortex [42,43], indicates that differential regulation of M1-
M5; M1, M3, and M4 were upregulated whereas M2 and M5 were
down  regulated  in  response  to  chronic  administration  of
atropine. Thus, at both the protein and message level, these
two receptor systems seem to be about equal in abundance in
cortex.
In rat cerebellar cells, M2 and M3 mRNAs were down
regulated with carbachol treatment [44] however, antagonist
induced upregulation of M2 and M3 mRNA level [45]. In rabbit
tracheal  smooth  muscle,  M3  was  upregulated  following
atropine treatment [46]. In guinea pig posterior sclera, M1 and
M4 mRNA levels were increased after induction of form-
deprived myopia [47]. It is clear that the regulation of M1-
M5 subtypes varies between species and different tissues or
cell types. Differential expression of muscarinic receptors
suggests  that  different  routes  of  administration  and
concentrations  of  atropine  would  have  influence  on  the
mRNA levels.
In  conclusion,  we  have  confirmed  that  atropine
effectively reduces progression of myopia in both pigmented
and  non-pigmented  mice.  Muscarinic  receptor  antagonists
most certainly seem to be promising drugs to inhibit human
myopia. Additional knowledge on the actions of the drug, its
toxicity and the mechanism are required. We have determined
the  mechanism  of  atropine  at  the  gene  expression  level
however there are avenues to be explored on the molecular
and protein level. In this regard, the study of changing patterns
of  gene  expression  within  and  among  species  during
emmetropization  and  myopic  progression  may  offer  a
productive avenue for future research. Elucidating deficient
steps  in  the  regulatory  pathway  would  mark  significant
advance  given  myopia's  tremendous  impact.  No  data  are
available on the systemic toxic effect in the long term usage
of atropine. By studying the atropine treatment on muscarinic
knock out mouse model would help us in understanding the
effect of long-term usage of atropine or specific muscarinic
blockers in human subjects and further investigations that
need to be conducted with new therapeutic agents to treat
myopia with this new model.
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